Creating opportunities from uncertainty: navigating industrial emergence

Industrial Symposium: 24th and 25th September 2009, Downing College, Cambridge, UK

Speakers

David Bott

David was appointed as Director of Innovation Platforms in the Technology Strategy Board in July 2007. He was then made Director of Innovation Programmes in July 2008.

David graduated from the University of Sussex with a BSc in Polymer Science. He stayed on to do a PhD sponsored by ICI Plastics, spending the summers working in their laboratories at Welwyn Garden City. As a result of this experience, he joined the British Petroleum Research Centre at Sunbury-on-Thames where he led a team working on electrically conductive polymers, polymer batteries and non-linear optics. 8 years later he joined Courtaulds to set up and run their Strategic Research Group. In addition he spent separate years responsible for Carbon Fibre Research (1989) and Performance Films (1992)(in America). After another 8 years he left to join ICI Acrylics as Research Director. He then joined National Starch, where he was responsible for research in their Specialty Synthetic Resins Division for 2 years and then became a Director of Group Technology for ICI.

Throughout this time, he has sat on the UK Governments Technology Foresight Panel for Materials, was President of the Industrial Affairs Division of the Royal Society of Chemistry (2002-2004) and the Co-Chairman of the Strategy and Implementation Board of the Crystal Faraday Partnership on Green Chemistry (2001 – 2007). He is Chairman of Oxford Biomaterials and a Director of Apaclara and Spineless Design. He is also an advisor to FirstVentures, a Venture Capital Fund focusing on advanced materials and nanotechnology. From 2006 until 2008 he was part time CEO of Materials UK, a organisation set up to implement and develop the work of the Materials Innovation and Growth team.

Patrick Ginty

Patrick holds a PhD in tissue engineering and has a background in both Biology (BSc) and Biotechnology (MSc) with experience in both the healthcare industry and the NHS. After completing his post-doctoral fellowship at Nottingham University, he moved onto RegenTec Ltd, leading the development of an injectable scaffold product. Patrick is currently working with SMEs as part of the remedi project, whilst also training in FDA/EU regulatory affairs.

Andrew Haslett

Andrew Haslett joined the Energy Technologies Institute as Director - Strategy Development in April 2008 from his previous role as Group Science & Technology Director (Measurement & Modelling) at ICI plc.

Andrew has been involved in process and product technology development for 30 years, leading a range of research and engineering groups. His experience covers a very wide range of technologies from large scale high hazard process plant engineering to developing electronic materials and also a broad range of industrial and consumer applications. He has experience of development, design and operation of large scale plant and also technology licensing and the sale of technology based services.

At ICI, he was recently responsible for the development of the Group Technology Strategy and for assisting businesses to measure and improve their application of technology to innovation.

Andrew graduated from Cambridge University in 1977 with a BA in Chemical Engineering. He is a Fellow of the Royal Academy of Engineering, of the Institution of Chemical Engineers and the Royal Society for the encouragement of Arts, Manufactures & Commerce. He is a Chartered Engineer and a Chartered Scientist.

David Connell

David Connell splits his time between Directorships and board advisory roles for TTP Capital Partners and several small technology companies with a part time academic research position at the Centre for Business Research at the University of Cambridge since 2006.

He was previously founding Chief Executive of TTP Ventures, a Cambridge based venture capital fund specialising in early stage science and technology based ventures with funding from Boeing, Siemens and financial institutions. Its investments included spin-offs from Toshiba, Aventis, Oxford Instruments, Cambridge Consultants and Cambridge University.

From 1989 to 1997 David was Head of TTP Group’s Strategy Division, providing consulting advice on R&D management, technology exploitation, innovation and business development strategy to a wide range of clients included Shell, BP, IBM, Nortel, ICI, Barclays Bank and Cambridge University. Prior to joining TTP in 1989, David was responsible for Deloitte Haskins and Sells’ national UK High Technology Group based in the City of London.

In 2004, David launched a campaign with Anne Campbell, then MP for Cambridge, to persuade the UK Government to establish a US style Small Business Innovation Research programme. Their detailed proposals were endorsed in "Race to the Top", Lord Sainsbury's 2007 review of UK science and innovation policy and David is an advisor to the Technology Strategy Board on implementing this policy.

David has a BSc in Physics and Masters Degrees in Economics and Operational Research.

John Cunliffe

Chief Technology Officer, Ericsson Ltd.

John's CTO role at Ericsson Ltd incorporates a wide range of responsibilities including, working with customers, research, government and regulatory affairs and UK R&D activities. He has a broad understanding of the telecoms industry from both technology and business perspectives.

Previously, John was at Marconi where with responsibilities for network vision, technology strategy, research and regulation. Earlier in his career his R&D responsibilities included data products, fibre to the home, call control and fault tolerant computing.

John is a Chartered Engineer, a Fellow of the Institute of Engineering and Technology (IET) and a board member at Intellect.

Dr David Fyfe

David Fyfe has long experience in leading internationally focused commercial businesses and growing them organically, by acquisition, joint ventures and partnerships. In 2000 David became Chairman and CEO of Cambridge Display Technology, a 1992 spinout from Cambridge University developing P-OLED technology. In these positions he grew CDT into a commercial business through a combination of organic growth, acquisition of three complementary technology companies, partnership with a number of predominantly Asian companies and a joint venture with Sumitomo Chemical for P-OLED materials development and commercialisation. He led the company to a listing on Nasdaq in 2004, raised over $120 million in funding in private and public placing and in September 2007 led a merger with Sumitomo Chemical which gave CDT shareholders $285 million in cash.

Dr Andrew Flewitt

Dr Andrew Flewitt, who is a member of the Cambridge University Department of Engineering, received his PhD from the University of Cambridge in 1998 investigating the growth of hydrogenated amorphous silicon thin films using scanning tunnelling microscopy. He stayed in the Engineering Department following the PhD as a Research Associate sponsored by Philips Research Laboratories working on the low temperature fabrication of thin film transistors for liquid crystal displays. He was appointed to Lectureship in August 2002 and promoted to Senior Lecturer in 2006. Current research interests include the degradation mechanisms of amorphous silicon thin films transistors, zinc oxide thin film transistors, nanowire-polymer composite semiconductor materials and MEMS-based biological sensing devices using surface acoustic wave technology.

Richard Guy

A Senior Technology Acceleration Manager at the Carbon Trust, Richard leads the Carbon Trust’s field trials and demonstration projects in buildings and industry – overcoming market barriers to the adoption of new technologies. Prior to joining the Carbon Trust’s Innovations team in 2006, Richard worked as a consultant engineer in the defence, aerospace and nuclear power sectors.

The Carbon Trust is an independent company funded by the UK Government. Its mission is to accelerate the move to a low-carbon economy by working with organisations to reduce carbon emissions and supporting the development of low-carbon technologies.

Dr Andrew Herbert

Dr Andrew Herbert is a Distinguished Engineer and Managing Director of Microsoft Research in Cambridge, England.  Before joining Microsoft Research in 2001, he was Director of Advanced Technology at Citrix Systems Inc.  He joined Citrix in 1998 from Digitivity Inc which he had founded in 1996 to develop a product to enable for secure deployment of Java clients for business-to-business applications.  Digitivity was a spin out from APM Ltd, a research / consulting company he founded in 1985.  APM managed ANSA, an industry-sponsored program of research and advanced development into the use of distributed systems technology to support applications integration in enterprise-wide systems.

Andrew is a Fellow of The Royal Academy of Engineering, a Fellow of Wolfson College Cambridge, England, a member of St John's College Cambridge, a Visiting Professor at University College London  and a Liveryman of the City of London Worshipful Company of Information Technologists. He has a BSc in Computational Science from the University of Leeds and a PhD. in Computer Science from Cambridge University.

Andrew's research interests include networks, operating systems, programming languages and distributed computing.

Dr Jackie Hunter

Dr Jackie Hunter has worked in the pharmaceutical industry for over 20 years, after carrying our post doctoral research at St George’s Hospital Medical School in London. For most of her industrial career she has focussed on the discovery of drugs for serious neurological diseases such as Parkinson’s disease. Most recently, in her role as head of the Neurology Centre of Excellence for Drug Discovery at GlaxoSmithKline, she led the discovery and development of new therapeutics for neurological and gastrointestinal disorders. This resulted in potential new treatments for multiple sclerosis, Alzheimer’s disease and GI disorders. She has published over 130 scientific papers and served on a number of industrial and academic boards. Currently she is a member of the BBSRC Council, The Wellcome Trust Molecular and Physiological Sciences Strategy Committee and on the Board of Molecular Medicine Ireland.

In 2008 she became the Senior Vice President & Head of Science Environment Development with a remit to develop a more open and transparent global R&D architecture. This includes new ways of working with academia and other publically funded bodies. In her current role she is actively involved in driving forward the Innovative Medicines Initiative for Europe and is an IMI Board member.

James Lawford Davies

James is a Lecturer in Law and Medicine at the University of Newcastle, a Visiting Research Fellow at Durham University Law School and a Senior Associate at Clifford Chance in London. He specialises in the law relating to reproductive and genetic technologies, human tissue and cells, and related research.

James advises a large number of clinics and research centres licensed by the Human Fertilisation and Embryology Authority (HFEA) and has been involved in most of the leading cases relating to assisted reproduction and related research. James has advised widely on the regulatory and commercial issues relating to embryo and embryonic stem cell research, including cell nuclear replacement, human-animal hybrids research, import and export, and the implications of EU law.

Dr Andrew Lynn

Dr Andrew Lynn received his PhD in Materials Science from the University of Cambridge. His experience in the field of orthopaedics and regenerative medicine spans nine years and four countries; it includes the initiation, management, and implementation of product-focused programmes involving artificial prostheses for joint replacement and tissue regeneration scaffolds for orthopaedic, neurosurgical, and thoracic applications. He has worked extensively with world-renowned surgeons on initiatives to develop and commercialise regenerative medical treatments for a range of clinical conditions.

Dr Lynn founded Orthomimetics (OM) in March 2005 on the basis of his doctoral research conducted in conjunction with a team of surgeons, scientists and engineers from the University of Cambridge, the Massachusetts Institute of Technology, and Harvard University. Under Dr Lynn's tenure as CEO, Orthomimetics has raised £5.6m in Series A funding and a further £2.3m in grant funding, achieved CE Mark approval for and first human use of the company's flagship product and developed a strong product pipeline for the treatment of a variety of musculoskeletal conditions.

OM continues to work closely with the University of Cambridge in the development of its product pipeline. The successful transition from university-based researcher to CEO of an independent company has earned Dr Lynn the 2008 European Academic Enterprise Award for University Entrepreneurs in Chemistry and Materials and Orthomimetics the 2008 Cambridge Business Excellence Rising Star Award.

Dr John Pritchard

John Pritchard is Chief Technical Officer at Smart Holograms. He has over twenty years of international management experience from companies such as Boehringer Mannheim, Genzyme and Hypoguard. He has been responsible for managing the development of products ranging from blood glucose biosensors to immunoassay analysers and reagents as well as the assessment of novel diagnostic technologies. At Boehringer Mannheim he was responsible for the development of the first generation biosensor test strip for the Accuchek ® Advantage ™ blood glucose monitoring system as well as the development of the second-generation product targeted at the hospital segment (this blockbuster product has generated over $1 billion in annual sales revenue worldwide). In addition, John has been a Managing Consultant at PA Consulting Group where he was a leading member of their Healthcare group. John was also a CEO of Akubio which he successfully matured in its first few years from a Cambridge University spin-out to an early-stage firm. More recently, he was the Chief Scientific Officer of Hypoguard (listed on the London Stock Exchange) which develops glucose sensors for diabetics. He has a PhD in Biochemistry from Liverpool University and an MBA from Boston University. John joined Smart in November 2005

Professor David J Williams

David has been "Star Professor" in Healthcare Engineering in the Department of Mechanical and Manufacturing Engineering, Loughborough University since 2003. He is Director of the university Research School of Health and Life Sciences. He leads both the national £8m EPRSC Innovative Manufacturing Grand Challenge in Regenerative Medicine - a new industry and a £6.1m EPSRC Doctoral Training Centre in Regenerative Medicine. Between 1999 and 2003 David was Technical Director of Bespak, a major supplier of drug delivery devices to the pharmaceutical industry. This followed ten years as Professor of Manufacturing Processes at Loughborough. His early career, while including industrial jobs with GKN and Metal Box, was primarily within the Cambridge University Engineering Department. David was elected a Fellow of the Royal Academy of Engineering in 2002 and holds the PhD degree of Cambridge University and DEng degree of UMIST/University of Manchester. David is also a Chartered Engineer, Fellow of the Institution of Mechanical Engineers and Fellow of the Royal Society of Medicine.